Impairment of glyoxalase-1, an advanced glycation end-product detoxifying enzyme, induced by inflammation in age-related osteoarthritis.


Journal

Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438

Informations de publication

Date de publication:
11 01 2019
Historique:
received: 22 08 2018
accepted: 20 12 2018
entrez: 13 1 2019
pubmed: 13 1 2019
medline: 31 3 2020
Statut: epublish

Résumé

Accumulation of advanced glycation end-products (AGEs) is involved in age-related osteoarthritis (OA). Glyoxalase (Glo)-1 is the main enzyme involved in the removal of AGE precursors, especially carboxymethyl-lysine (CML). We aimed to investigate the expression of several AGEs and Glo-1 in human OA cartilage and to study chondrocytic Glo-1 regulation by inflammation, mediated by interleukin (IL)-1β. Ex vivo, we quantified AGEs (pentosidine, CML, methylglyoxal-hydroimidazolone-1) in knee cartilage from 30 OA patients. Explants were also incubated with and without IL-1β, and we assessed Glo-1 protein expression and enzymatic activity. In vitro, primary cultured murine chondrocytes were stimulated with increasing concentrations of IL-1β to assess Glo-1 enzymatic activity and expression. To investigate the role of oxidative stress in the IL-1β effect, cells were also treated with inhibitors of mitochondrial oxidative stress or nitric oxide synthase. Ex vivo, only the human cartilage CML content was correlated with patient age (r = 0.78, p = 0.0031). No statistically significant correlation was found between Glo-1 protein expression and enzymatic activity in human cartilage and patient age. We observed that cartilage explant stimulation with IL-1β decreased Glo-1 protein expression and enzymatic activity. In vitro, we observed a dose-dependent decrease in Glo-1 mRNA, protein quantity, and enzymatic activity in response to IL-1β in murine chondrocytes. Inhibitors of oxidative stress blunted this downregulation. Glo-1 is impaired by inflammation mediated by IL-1β in chondrocytes through oxidative stress pathways and may explain age-dependent accumulation of the AGE CML in OA cartilage.

Sections du résumé

BACKGROUND
Accumulation of advanced glycation end-products (AGEs) is involved in age-related osteoarthritis (OA). Glyoxalase (Glo)-1 is the main enzyme involved in the removal of AGE precursors, especially carboxymethyl-lysine (CML). We aimed to investigate the expression of several AGEs and Glo-1 in human OA cartilage and to study chondrocytic Glo-1 regulation by inflammation, mediated by interleukin (IL)-1β.
METHODS
Ex vivo, we quantified AGEs (pentosidine, CML, methylglyoxal-hydroimidazolone-1) in knee cartilage from 30 OA patients. Explants were also incubated with and without IL-1β, and we assessed Glo-1 protein expression and enzymatic activity. In vitro, primary cultured murine chondrocytes were stimulated with increasing concentrations of IL-1β to assess Glo-1 enzymatic activity and expression. To investigate the role of oxidative stress in the IL-1β effect, cells were also treated with inhibitors of mitochondrial oxidative stress or nitric oxide synthase.
RESULTS
Ex vivo, only the human cartilage CML content was correlated with patient age (r = 0.78, p = 0.0031). No statistically significant correlation was found between Glo-1 protein expression and enzymatic activity in human cartilage and patient age. We observed that cartilage explant stimulation with IL-1β decreased Glo-1 protein expression and enzymatic activity. In vitro, we observed a dose-dependent decrease in Glo-1 mRNA, protein quantity, and enzymatic activity in response to IL-1β in murine chondrocytes. Inhibitors of oxidative stress blunted this downregulation.
CONCLUSION
Glo-1 is impaired by inflammation mediated by IL-1β in chondrocytes through oxidative stress pathways and may explain age-dependent accumulation of the AGE CML in OA cartilage.

Identifiants

pubmed: 30635030
doi: 10.1186/s13075-018-1801-y
pii: 10.1186/s13075-018-1801-y
pmc: PMC6330409
doi:

Substances chimiques

Glycation End Products, Advanced 0
Inflammation Mediators 0
GLO1 protein, human EC 4.4.1.5
Lactoylglutathione Lyase EC 4.4.1.5

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

18

Subventions

Organisme : Fondation Arthritis
ID : ROAD Network
Pays : International
Organisme : Fondation Arthritis
ID : ROAD network
Pays : International
Organisme : Sorbonne Université
ID : Programme Convergence
Pays : International
Organisme : Sorbonne Université
ID : Programme Convergence
Pays : International

Références

J Gerontol A Biol Sci Med Sci. 2014 Jun;69 Suppl 1:S4-9
pubmed: 24833586
Diabetes Obes Metab. 2007 May;9(3):233-45
pubmed: 17391149
Toxicol Sci. 2013 Jul;134(1):39-48
pubmed: 23564646
Arthritis Res Ther. 2018 Jun 22;20(1):131
pubmed: 29929535
J Pediatr. 2016 May;172:56-62
pubmed: 26947567
Biochim Biophys Acta. 2008 May;1783(5):713-27
pubmed: 18241676
J Biol Chem. 2006 Apr 28;281(17):11864-71
pubmed: 16505483
Diabetes. 2016 Aug;65(8):2282-94
pubmed: 27207552
Lancet. 2011 Jun 18;377(9783):2115-26
pubmed: 21684382
Nat Rev Rheumatol. 2016 Jul;12(7):412-20
pubmed: 27192932
Rheumatology (Oxford). 2011 May;50(5):838-51
pubmed: 21172926
Curr Opin Rheumatol. 2017 Jan;29(1):79-85
pubmed: 27755180
Acta Histochem. 2011 Oct;113(6):613-8
pubmed: 20656335
Osteoarthritis Cartilage. 2015 Nov;23(11):1955-65
pubmed: 26033164
Arthritis Rheum. 2002 Jan;46(1):114-23
pubmed: 11822407
Histochem Cell Biol. 2002 Jun;117(6):541-6
pubmed: 12107505
Rheumatology (Oxford). 2011 Aug;50(8):1379-89
pubmed: 21482542
J Am Med Dir Assoc. 2013 Dec;14(12):877-82
pubmed: 23792036
Exp Dermatol. 2016 Jun;25(6):492-4
pubmed: 26914966
Aging Cell. 2017 Apr;16(2):210-218
pubmed: 28124466
Arthritis Rheum. 1997 Apr;40(4):723-7
pubmed: 9125256
Semin Cell Dev Biol. 2011 May;22(3):293-301
pubmed: 21320620
Arthritis Rheum. 2003 Dec;48(12):3419-30
pubmed: 14673993
Aging Cell. 2008 Mar;7(2):260-9
pubmed: 18221415
Curr Rheumatol Rep. 2003 Feb;5(1):33-40
pubmed: 12590883
PLoS One. 2015 May 29;10(5):e0125776
pubmed: 26024533
Arthritis Rheumatol. 2015 Nov;67(11):2905-15
pubmed: 26195278
Clin Chem Lab Med. 2014 Jan 1;52(1):33-8
pubmed: 23454717
Biochem J. 2012 Apr 1;443(1):213-22
pubmed: 22188542
Osteoarthritis Cartilage. 2005 Mar;13(3):243-9
pubmed: 15727891
Ageing Res Rev. 2017 Nov;40:20-30
pubmed: 28774716
Semin Cell Dev Biol. 2011 May;22(3):309-17
pubmed: 21335095
Methods Enzymol. 1996;268:375-92
pubmed: 8782604
Antioxid Redox Signal. 2018 Dec 10;29(17):1727-1745
pubmed: 28899199
J Gerontol A Biol Sci Med Sci. 2005 Sep;60(9):1118-24
pubmed: 16183949
Gerontology. 2017;63(1):29-35
pubmed: 27595269
Free Radic Biol Med. 2011 Oct 1;51(7):1289-301
pubmed: 21777669
Genet Mol Res. 2016 May 09;15(2):
pubmed: 27173350
J Biol Chem. 2017 Sep 1;292(35):14505-14515
pubmed: 28684418
Osteoarthritis Cartilage. 2014 Feb;22(2):259-63
pubmed: 24333294
Gene. 1999 Nov 15;240(1):149-55
pubmed: 10564821
Osteoarthritis Cartilage. 2012 Mar;20(3):233-40
pubmed: 22227209
Biochem Soc Trans. 2014 Apr;42(2):538-42
pubmed: 24646275
Osteoarthritis Cartilage. 2015 Sep;23(9):1513-22
pubmed: 25987541
Biochem J. 2000 Sep 1;350 Pt 2:381-7
pubmed: 10947951
Biochem J. 1999 Nov 15;344 Pt 1:109-16
pubmed: 10548540
Am J Physiol Renal Physiol. 2005 Oct;289(4):F645-59
pubmed: 16159899
Nat Protoc. 2008;3(8):1253-60
pubmed: 18714293
Arthritis Rheum. 2009 Jul;60(7):2037-45
pubmed: 19565477
Cardiovasc Res. 2007 Jul 15;75(2):261-74
pubmed: 17498676
Thromb Res. 2014 Sep;134(3):633-8
pubmed: 25065554
Ann N Y Acad Sci. 2000 Jun;908:244-54
pubmed: 10911963
Amino Acids. 2012 Apr;42(4):1133-42
pubmed: 20963454
J Gerontol A Biol Sci Med Sci. 2014 Feb;69(2):165-73
pubmed: 23689826
Ann Rheum Dis. 2014 Jul;73(7):1323-30
pubmed: 24553908
Arthritis Rheum. 2012 Jun;64(6):1940-9
pubmed: 22231515
Diabetes Metab Res Rev. 2014 Nov;30(8):679-85
pubmed: 24449227

Auteurs

Sabine Trellu (S)

Sorbonne University, UPMC Univ Paris 06, Paris, France.
INSERM UMRS_938, CRSA, Paris, France.
Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Paris, France.
Department of Rheumatology, Assistance Publique - Hôpitaux de Paris (AP-HP), Saint-Antoine Hospital, 184 rue du Faubourg Saint-Antoine, 75012, Paris, France.

Alice Courties (A)

Sorbonne University, UPMC Univ Paris 06, Paris, France.
INSERM UMRS_938, CRSA, Paris, France.
Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Paris, France.
Department of Rheumatology, Assistance Publique - Hôpitaux de Paris (AP-HP), Saint-Antoine Hospital, 184 rue du Faubourg Saint-Antoine, 75012, Paris, France.

Stéphane Jaisson (S)

UMR MEDyC CNRS/URCA 7369, University of Reims Champagne-Ardenne, Reims, France.

Laëtitia Gorisse (L)

UMR MEDyC CNRS/URCA 7369, University of Reims Champagne-Ardenne, Reims, France.

Philippe Gillery (P)

UMR MEDyC CNRS/URCA 7369, University of Reims Champagne-Ardenne, Reims, France.

Saadia Kerdine-Römer (S)

INSERM UMR 996, Univ Paris-Sud, University Paris-Saclay, Châtenay-Malabry, France.

Carlos Vaamonde-Garcia (C)

Sorbonne University, UPMC Univ Paris 06, Paris, France.
INSERM UMRS_938, CRSA, Paris, France.
Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Paris, France.
Department of Physiotherapy, Cell Therapy and Regenerative Medicine Group, Medicine and Biological Science. Faculty of Health Sciences, University of A Coruña, 15006, A Coruña, Spain.

Xavier Houard (X)

Sorbonne University, UPMC Univ Paris 06, Paris, France.
INSERM UMRS_938, CRSA, Paris, France.
Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Paris, France.

François-Paul Ekhirch (FP)

Groupe Maussins, Clinique des Maussins-Ramsay, Générale de Santé, Paris, France.

Alain Sautet (A)

Sorbonne University, UPMC Univ Paris 06, Paris, France.
Department of Orthopedic Surgery, AP-HP, Saint-Antoine Hospital, Paris, France.

Bertrand Friguet (B)

Sorbonne University, UPMC Univ Paris 06, Paris, France.
UMR 8256 - IBPS, CNRS UMR 8256, INSERM U1164, F-75005, Paris, France.

Claire Jacques (C)

Sorbonne University, UPMC Univ Paris 06, Paris, France.
INSERM UMRS_938, CRSA, Paris, France.
Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Paris, France.

Francis Berenbaum (F)

Sorbonne University, UPMC Univ Paris 06, Paris, France. francis.berenbaum@aphp.fr.
INSERM UMRS_938, CRSA, Paris, France. francis.berenbaum@aphp.fr.
Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Paris, France. francis.berenbaum@aphp.fr.
Department of Rheumatology, Assistance Publique - Hôpitaux de Paris (AP-HP), Saint-Antoine Hospital, 184 rue du Faubourg Saint-Antoine, 75012, Paris, France. francis.berenbaum@aphp.fr.

Jérémie Sellam (J)

Sorbonne University, UPMC Univ Paris 06, Paris, France.
INSERM UMRS_938, CRSA, Paris, France.
Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Paris, France.
Department of Rheumatology, Assistance Publique - Hôpitaux de Paris (AP-HP), Saint-Antoine Hospital, 184 rue du Faubourg Saint-Antoine, 75012, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH